Cost-effectiveness of Dabigatran versus genotype-guided management of Warfarin therapy for stroke prevention in patients with Atrial fibrillation

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  You, Joyce H S ^a   Tsui, Kia K N ^a   Wong, Raymond S M ^a   Cheng, Gergory ^a  

^a Chinese University of Hong Kong   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN; WARFARIN;

AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CHADS2 SCORE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYP2C9 GENE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE; GENOTYPE; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; STROKE; SYSTEMATIC REVIEW; VKORC1 GENE;

EID: 84862649728     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039640     Document Type: Article

References (42)

1. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, et al. (2008) Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118: 2029-37.
2. You JHS, Chan FWH, Wong RSM, Cheng G, (2005) Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 59: 582-7.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-51.
4. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, et al. (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376: 975-83.
5. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, et al. (2011) Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fribrillation. Ann Intern Med 154: 1-11.
6. Shah SV, Gage BF, (2011) Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 123: 2562-70.
7. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, et al. (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116: 2563-70.
8. Eckman MH, Rosand R, Greenberg SM, Gage BF, (2009) Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with non-valvular atrial fibrillation. Ann Intern Med 150: 73-83.
9. You JHS, Tsui KKN, Wong RSM, Cheng G, (2009) Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients initiating warfarin therapy. Clin Pharmacol Ther 86: 540-7.
10. Epstein RS, Moyer TP, Aubert R, O'Kane DJ, Xia F, et al. (2010) Warfarin genotyping reduces hospitalization rates. J Am Coll Cardiol 55: 2804-12.
11. The International Warfarin Pharmacogenetics Consortium, (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360: 753-64.
12. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, et al. (2004) Warfarin anticoagulation and outcomes in patients with atrial fibrillation. A systematic review and metaanalysis. Chest 126: 1938-45.
13. Stroke Prevention in Atrial Fibrillation Investigators, (1996) Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348: 633-8.
14. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, et al. (2004) Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110: 2287-92.
15. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, et al. (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349: 1019-26.
16. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, et al. (2002) Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 288: 2441-8.
17. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, et al. (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370: 493-503.
18. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, et al. (2007) Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 120: 700-5.
19. Hanger CH, Fletcher VJ, Wilkinson TJ, Brown AJ, Frampton CM, et al. (2008) Effect of aspirin and warfarin on early survival after intracerebral haemorrhage. J Neurol 255: 347-52.
20. Gage BF, Cardinalli AB, Owen DK, (1996) The effect of stroke and stroke prophylaxis with aspirin and warfarin on quality of life. Arch Intern Med 156: 1829-36.
21. Thomson R, Parkin D, Ecclles M, Sudlow M, Robinson A, (2000) Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 355: 956-62.
22. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, et al. (1993) The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 13: 89-102.
23. Sullivan PW, Ghushchyan V, (2006) Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 26: 410-20.
24. Delaney BC, Qume M, Moayyedi P, Logan RF, Ford AC, et al. (2008) Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomized control trial (MRC-CUBE trial). BMJ 336: 651-4.
25. Centers for Medicare & Medicaid Services website (2011) Assessed on 11 Nov 2011. Available:http://www.cms.gov/MedicareFeeforSvcPartsAB/03_MEDPAR.asp.
26. Agency for Healthcare Research and Policy. HCUPnet. Accessed: 11 Nov Available:http://hcupnet.ahrq.gov/. (2011)
27. Mark DB, Knight JD, Cowper PA, Davidson-Ray L, Anstrom KJ, (2008) Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. Am Heart J 156: 698-705.
28. Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, et al. (2001) Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 141: 727-34.
29. Menzin J, Boulanger L, Hauch O, Friedman M, Marple CB, et al. (2005) Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: A multi-site managed-care study. Ann Pharmacother 39: 446-51.
30. Chan FWH, Wong RSM, Lau WH, Chan TYK, Cheng G, et al. (2006) Management of Chinese patients on warfarin therapy in two models of anticoagulation service - A prospective randomized trial. Br J Clin Pharmacol 62: 601-9.
31. Drugstore.com. Accessed: Nov 11 Available:www.drugstore.com. (2011)
32. Maurice CB, Barua PK, Simses D, Smith P, Howe JG, et al. (2010) Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping. Clinica Chimica Acta 411: 947-54.
33. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB, (1996) Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 276: 1253-8.
34. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, et al. (2010) Newly dentified events in the RE-LY trial. N Engl J Med 363: 1875-6.
35. Uchino K, Hernandez AV, (2012) Dabigatran association with higher risk of acute coronary events. Arch Intern Med published on-line doi.
36. Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, et al. (2011) Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective. Throm Haemost 105: 908-19.
37. You JHS, Wong RSM, Waye MMY, Mu Y, Lim CK, et al. (2011) Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. J Thromb Thrombolysis 31: 113-8.
38. You JHS, (2011) Pharmacoeconomic evaluation of warfarin pharmacogenomics. Expert Opin Pharmacother 12: 435-41.
39. ACTIVE Writing Group on behalf of the ACTIVE Investigators (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel TrialWith Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367: 1903-12.
40. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, et al. (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706-17.
41. Bernheim SM, Grady JN, Lin Z, Wang Y, Wang Y, et al. (2010) National patterns of risk-standardized mortality and readmission for acute myocardial infarction and heart failure: Update on publicly reported outcomes measures based on the 2010 release. Circ Cardiovasc Qual Outcomes 3: 459-67.
42. O'Brien CL, Gage BF, (2005) Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 293: 699-706.